
Table of Contents

Abbreviations	XXV	2.11 The ancestral cult	38		
		2.12 Social impact	39		
		2.13 The discovery of transmissibility	40		
		2.14 The answers to the questions	41		
<hr/>					
Topic I: History					
<hr/>					
1	Historical Introduction	3	3	History of Prion Research	44
	<i>B. Hörlmann, D. Riesner, H. Kretzschmar, R. G. Will, S. C. MacDiarmid, G. A. H. Wells, and M. P. Alpers</i>			<i>S. B. Prusiner</i>	
1.1	Introduction	3	3.1	Introduction	44
1.2	The cause of prion diseases	3	3.2	Animals and humans affected	44
1.3	Scrapie: archetype of all prion diseases ..	4	3.3	In search of the cause	46
1.4	Transmissible mink encephalopathy	7	3.4	Amazing discovery	46
1.5	Chronic wasting disease in North American cervids	7	3.5	Prion diseases can be inherited	47
1.6	Creutzfeldt-Jakob disease and other human prion diseases	8	3.6	One protein, two shapes	51
1.7	The scrapie-kuru connection	11	3.7	Treatment ideas emerge	51
1.8	Etiological variety of prion diseases	12	3.8	The mystery of “strains”	52
1.9	New prion diseases	14	3.9	Breaking the barrier	53
1.10	Prion diseases and contagion	18	3.10	The list may grow	54
1.11	Summary: traits common to all human and animal prion diseases	18	3.11	Striking similarities	54
1.12	Synopsis of events, discoveries and findings since 1732	19			
2	History of Kuru Research	28	<hr/>		
	<i>B. Hörlmann</i>		Topic II: Molecular Biology and Genetics		
			<hr/>		
2.1	Introduction	28	4	The Physical Nature of the Prion ..	59
2.2	From the stone age to the present: the Fore people	28		<i>D. Riesner</i>	
2.3	Discovery of kuru	29	4.1	Introduction	59
2.4	The “Tukabu” ritual	32	4.2	The prion model and its nomenclature ..	59
2.5	The beginning of kuru research	32	4.3	The virus hypothesis	60
2.6	A kuru hospital in Okapa	33	4.4	The virino hypothesis	61
2.7	The spread of kuru	34	4.5	The nucleic acid problem	61
2.8	The pathological picture	35	5	Folding of the Recombinant Prion Protein	69
2.9	The diet of the Fore	36		<i>R. Glockshuber, J. Stöhr, and D. Riesner</i>	
2.10	The geographical spread of the epidemic and the phylogenetic relations among kuru victims	37	5.1	Introduction	69
			5.2	Folding of recombinant PrP ^C	70
			5.3	The role of the single disulfide bond of PrP	73
			5.4	Influence of point mutations linked with inherited human prion diseases on the ther- modynamic stability of recombinant PrP ^C	74

5.5	Outlook	76	9.3	Comparative analysis of PrP genes and prion proteins	121
6	Structural Studies of Prion Proteins <i>S. Schwarzinger, D. Willbold, and J. Ziegler</i>	79	10	Knockouts and Transgenic Mice in Prion Research	134
6.1	Introduction	79		<i>E. Flechsig, I. Hegyi, A.J. Raeber, A. Cozzio, A. Aguzzi, and C. Weissmann</i>	
6.2	Structure of the globular domain of PrP ^C	81	10.1	Introduction	134
6.3	Structural studies of full-length PrP	86	10.2	Generation and properties of PrP knockout mice	134
6.4	NMR studies on isolated structural features of PrP	88	10.3	Transgenesis and gene replacement	140
6.5	High pressure NMR	90	10.4	Reverse genetics: studies on the structure–function relationship of PrP	141
6.6	Structural studies of PrP ^{Sc}	91	10.5	Transgenic approaches to study intervention strategies against prion diseases ..	148
7	Function of Cellular Prion Protein in Copper Homeostasis and Redox Signaling at the Synapse	95	10.6	Investigating the mechanism of prion propagation by ectopic expression of PrP	150
	<i>J. Herms and H. Kretzschmar</i>		11	Transplantation as a Tool in Prion Research	160
7.1	Introduction	95		<i>E. Flechsig, I. Hegyi, A.J. Raeber, A. Cozzio, A. Aguzzi, and C. Weissmann</i>	
7.2	Cellular location of PrP ^C	95	11.1	Introduction	160
7.3	Protein interactions with PrP ^C	96	11.2	Prion-infected neurografts fail to cause neuropathological changes in PrP knockout mice	160
7.4	PrP ^C binds copper(II) ions	96	11.3	Spread of prions in the central nervous system requires PrP ^C -expressing tissue ..	161
7.5	Functional relevance of copper binding of PrP ^C at the synapse	97	11.4	Spread of prions from extracerebral sites to the CNS	162
7.6	Neuroprotective role of the prion protein in response to copper and oxidative stress	98	12	Prion Strains	166
7.7	Redox signaling by PrP ^C modulates intracellular calcium homeostasis and synaptic function	99		<i>M.H. Groschup, A. Gretzschel, and T. Kuczius</i>	
8	The Scrapie Isoform of the Prion Protein PrP ^{Sc} Compared to the Cellular Isoform PrP ^C	104	12.1	Introduction	166
	<i>D. Riesner</i>		12.2	Definition of the term “prion strain” ..	166
8.1	Introduction	104	12.3	Characteristics of prion strains	167
8.2	Biological and immunological properties of PrP ^{Sc}	104	12.4	Adaptation and selection	173
8.3	Chemical, biochemical, and physical properties of PrP ^{Sc}	105	12.5	Known prion strains in different species ..	174
8.4	Structure of PrP ^{Sc}	108	12.6	Explanatory approaches with regard to the development and existence of prion strains	179
8.5	In vitro conversion of PrP and the generation of infectivity	109	<hr/> Topic III: Portraits of Prion Diseases <hr/>		
8.6	Models of prion replication	113	13	Portrait of Kuru	187
8.7	Infectious, sporadic, and familial etiology of prion diseases	116		<i>B. Hörnlimann and M.P. Alpers</i>	
9	The Phylogeny of Mammalian and Nonmammalian Prion Proteins	119	13.1	History	187
	<i>H.M. Schätzl</i>		13.2	Forms or variants	187
9.1	Introduction	119	13.3	Incubation period, transmissibility, and susceptibility	187
9.2	The organization of the PrP gene	119			

13.4	Clinical signs and course of disease ...	188	16.9	Risk factors	213
13.5	Differential diagnoses	190	16.10	Surveillance, prevention, and control ..	213
13.6	Epidemiology	190			
13.7	Pathology	191	17	Portrait of Fatal Familial Insomnia and Sporadic Fatal Insomnia	216
13.8	Is kuru a new disease?	191		<i>H. Budka and E. Gelpi</i>	
13.9	Risk factors	191	17.1	History	216
13.10	Surveillance, prevention, and control ..	192	17.2	Forms or variants	216
13.11	Editor's note	192	17.3	Incubation period, transmissibility, and susceptibility	216
14	Portrait of Creutzfeldt-Jakob Disease	195	17.4	Clinical signs and course of disease ...	217
	<i>H. Budka</i>		17.5	Differential diagnoses	218
14.1	History	195	17.6	Epidemiology	218
14.2	Forms or variants	195	17.7	Pathology	218
14.3	Incubation period, transmissibility, and susceptibility	196	17.8	Are FFI and SFI new diseases?	220
14.4	Clinical signs and course of disease ...	197	17.9	Risk factors	220
14.5	Differential diagnoses	197	17.10	Surveillance, prevention, and control ..	220
14.6	Epidemiology	198			
14.7	Pathology	198	18	Portrait of Scrapie in Sheep and Goat	222
14.8	Is CJD a new disease?	198		<i>B. Hörnlimann, L. v. Keulen, M.J. Ulvund, and R. Bradley</i>	
14.9	Risk factors	199	18.1	History	222
14.10	Surveillance, prevention, and control ..	199	18.2	Forms or variants (scrapie agent strains)	223
15	Portrait of Variant Creutzfeldt- Jakob Disease	204	18.3	Incubation period, transmissibility, and susceptibility	223
	<i>R.G. Will and J.W. Ironside</i>		18.4	Clinical signs and course of disease ...	225
15.1	History	204	18.5	Differential diagnoses	226
15.2	Forms or variants	204	18.6	Epidemiology	226
15.3	Incubation period, transmissibility, and susceptibility	204	18.7	Pathology	227
15.4	Clinical signs and course of disease ...	205	18.8	Is scrapie a new disease?	227
15.5	Differential diagnoses	205	18.9	Risk factors	227
15.6	Epidemiology	205	18.10	Surveillance, prevention, and control ..	228
15.7	Pathology	206			
15.8	Is vCJD a new disease?	207	19	Portrait of Bovine Spongiform Encephalopathy in Cattle and Other Ungulates	233
15.9	Risk factors	208		<i>B. Hörnlimann, J. Bachmann, and R. Bradley</i>	
15.10	Surveillance, prevention, and control ..	208	19.1	History	233
16	Portrait of Gerstmann-Sträussler- Scheinker Disease	210	19.2	Forms or variants	234
	<i>H. Budka</i>		19.3	Incubation period, transmissibility, and susceptibility	236
16.1	History	210	19.4	Clinical signs and course of disease ...	239
16.2	Forms or variants	211	19.5	Differential diagnoses	239
16.3	Incubation period, transmissibility, and susceptibility	211	19.6	Epidemiology	240
16.4	Clinical signs and course of disease ...	212	19.7	Pathology and pathogenesis	240
16.5	Differential diagnoses	213	19.8	Is BSE a new disease?	243
16.6	Epidemiology	213	19.9	Risk factors	243
16.7	Pathology	213	19.10	Surveillance, prevention, and control ..	246
16.8	Is GSS a new disease?	213			

20	Portrait of Prion Diseases in Zoo Animals	250	23.3	Incubation period, transmissibility, and susceptibility	271
	<i>J.K. Kirkwood and A.A. Cunningham</i>		23.4	Clinical signs and course of disease . . .	271
20.1	History	250	23.5	Differential diagnoses	272
20.2	Forms or variants	250	23.6	Epidemiology	272
20.3	Incubation period, transmissibility, and susceptibility	251	23.7	Pathology	272
20.4	Clinical signs and course of disease . . .	251	23.8	Is FSE a new disease?	272
20.5	Differential diagnoses	251	23.9	Risk factors	273
20.6	Epidemiology	252	23.10	Surveillance, prevention, and control . .	273
20.7	Pathology	253	24	Portrait of Experimental BSE in Pigs	275
20.8	Are prion diseases of zoo animals new?	253		<i>G.A.H. Wells, S.A.C. Hawkins, J. Pohlenz, and D. Matthews</i>	
20.9	Risk factors	253	24.1	History	275
20.10	Surveillance, prevention, and control . .	254	24.2	Forms or variants	275
21	Portrait of Chronic Wasting Disease in Deer Species	257	24.3	Incubation period, transmission, and susceptibility	275
	<i>E.S. Williams and M.W. Miller</i>		24.4	Clinical signs and course of disease . . .	276
21.1	History	257	24.5	Differential diagnoses	276
21.2	Forms or variants	257	24.6	Epidemiology	276
21.3	Incubation period, transmissibility, and susceptibility	258	24.7	Pathology	276
21.4	Clinical signs and course of disease . . .	259	24.8	Is there a TSE of pigs?	277
21.5	Differential diagnoses	261	24.9	Risk factors	277
21.6	Epidemiology	261	24.10	Surveillance, prevention, and control . .	277
21.7	Pathology	262	25	Portrait of a Spongiform Encephalopathy in Birds and the Transmissibility of Mammalian Prion Diseases to Birds	279
21.8	Is CWD a new prion disease?	262		<i>G.A.H. Wells, J. Pohlenz, S.A.C. Hawkins, and D. Matthews</i>	
21.9	Risk factors	262	25.1	History	279
21.10	Surveillance, prevention, and control . .	262	25.2	Avian prion diseases?	279
22	Portrait of Transmissible Mink Encephalopathy	265	25.3	Transmission studies	280
	<i>W.J. Hadlow</i>		25.4	Clinical signs and course of the SE of ostriches	280
22.1	History	265	25.5	Differential diagnoses of the SE of ostriches	280
22.2	Forms or variants	265	25.6	Epidemiology of the SE of ostriches . . .	281
22.3	Incubation period, transmissibility, and susceptibility	265	25.7	Pathology of the SE of ostriches	281
22.4	Clinical signs and course of disease . . .	266	25.8	What is the significance of the SE of ostriches?	281
22.5	Differential diagnoses	267	25.9	Risk factors and prevention	281
22.6	Epidemiology	267	25.10	Surveillance	282
22.7	Pathology	268			
22.8	Is TME a new disease?	268			
22.9	Risk factors	268			
22.10	Surveillance, prevention, and control . .	268			
23	Portrait of Transmissible Feline Spongiform Encephalopathy	271	<hr/> Topic IV: Pathology <hr/>		
	<i>M. Hewicker-Trautwein and R. Bradley</i>		26	Pathology and Genetics of Human Prion Diseases	287
23.1	History	271		<i>H. Kretzschmar and P. Parchi</i>	
23.2	Forms or variants	271			

26.1	Introduction	287	29.2	Surveillance of patients on an out-patient and in-patient basis	339
26.2	Neuropathologic features of prion diseases in humans	288	29.3	Surveillance in neuropathological laboratories and diagnostic laboratories	341
26.3	PrP ^{Sc} in non-neuronal tissues	294	29.4	International cooperation and the importance of national health authorities	344
26.4	The human prion protein and prion protein gene (<i>PRNP</i>)	294	29.5	Epidemiological surveillance and case control studies	345
26.5	Neuropathological phenotypes of human prion diseases	299	29.6	The problem of possible phenotypic variation of disease caused by BSE prions in humans	345
26.6	Genetics of human prion diseases: phenotypes of familial (genetic) prion diseases	305			
27	The Pathology of Prion Diseases in Animals	315	30	Clinical Findings in Human Prion Diseases	347
	<i>G.A.H. Wells, S.J. Ryder, and W.J. Hadlow</i>			<i>M. Sturzenegger and R.G. Will</i>	
27.1	Introduction	315	30.1	Introduction	347
27.2	Pathology of scrapie in sheep and goats	315	30.2	Differential diagnosis and additional paraclinical investigations	349
27.3	Pathology of transmissible mink encephalopathy	318	30.3	Clinical features of Creutzfeldt–Jakob disease	352
27.4	Pathology of chronic wasting disease	318	30.4	Clinical features of variant CJD	355
27.5	Pathology of bovine spongiform encephalopathy	319	30.5	Clinical features of Gerstmann–Sträussler–Scheinker disease	356
27.6	Pathology of BSE in non domestic captive ungulate species	323	30.6	Clinical features of fatal familial insomnia	357
27.7	Pathology of feline spongiform encephalopathy	323	30.7	Clinical features of sporadic fatal insomnia	359
28	Pathophysiology of Prion Diseases Following Peripheral Infection	328	30.8	Clinical features of kuru	359
	<i>W.J. Schulz-Schaeffer, H. Kretzschmar, and M. Beekes</i>		30.9	Annex: historical classification	359
28.1	Introduction	328	31	Methods for the Clinical Diagnosis of Human Prion Diseases	363
28.2	Administration of the pathogen in animal experiments	328		<i>I. Zerr</i>	
28.3	Cell culture experiments	328	31.1	Introduction	363
28.4	Peripheral paths of infection	328	31.2	Electroencephalogram	365
28.5	Significance of the hematopoietic system, in particular the spleen	329	31.3	Analysis of cerebrospinal fluid	366
28.6	Species-specific differences	330	31.4	Imaging techniques	371
28.7	Neuronal spread of infection to the central nervous system	331	31.5	Sensitivity of clinical diagnostic tests in distinct molecular CJD subtypes	375
			31.6	Diagnostic procedure	377
<hr/>			32	Introduction to Surveillance for Animal Prion Diseases	382
Topic V: Surveillance, Clinical Aspects and Diagnostics				<i>B. Hörnlimann, M.G. Doherr, D. Matthews, and S.C. MacDiarmid</i>	
29	Introduction to Surveillance for Human Prion Diseases	339	32.1	Introduction	382
	<i>B. Hörnlimann, H. Kretzschmar, R.G. Will, O. Windl, and H. Budka</i>		32.2	Passive surveillance for animal prion diseases	383
29.1	Introduction	339			

32.3	“Active” surveillance for animal prion diseases	386	37	Creutzfeldt-Jakob Disease in Germany	433
33	Clinical Findings in Bovine Spongiform Encephalopathy	389		<i>I. Zerr, S. Poser, and H. Kretzschmar</i>	
	<i>E. Schieker, U. Braun, B. Hörnlimann, and T. Konold</i>		37.1	Introduction	433
33.1	Introduction	389	37.2	German CJD surveillance study	433
33.2	Clinical history and course of the disease	389	37.3	CJD epidemiology in Germany	434
33.3	Differential diagnosis of BSE	390	37.4	Prognostic factors in sporadic CJD	438
33.4	General clinical examination findings	390	38	The Epidemiology of Kuru	440
33.5	Neurological examination findings	390		<i>M. P. Alpers and B. Hörnlimann</i>	
33.6	Laboratory findings	395	38.1	Introduction	440
33.7	Examination at abattoirs – a diagnostic challenge	396	38.2	Frequency of cases and progression of the epidemic	440
34	Clinical Findings in Scrapie	398	38.3	The geographical spread and related cultural events	442
	<i>M. J. Ulvund</i>		38.4	Distribution according to sex and age	444
34.1	Introduction	398	38.5	Sociocultural background of the sex- and age-specific distribution	445
34.2	Case history	399	38.6	Explanation for the survival time curve (time of infection and infectious dose)	445
34.3	Findings of the general clinical examination	401	38.7	Explanation of kuru cases among children (modes of infection)	446
34.4	Differential diagnoses	401	38.8	Conclusion and present significance of kuru	447
34.5	Course of the disease	403	39	The Course of the BSE Epidemic – Retrospective Epidemiological Considerations	449
34.6	Findings of the neurological examination	404		<i>B. Hörnlimann, J. B. Ryan, and S. C. MacDiarmid</i>	
34.7	Laboratory findings	405	39.1	Introduction	449
35	Diagnosis of Bovine Spongiform Encephalopathy by Immunological Methods	408	39.2	Basic epidemiological data on BSE in the UK	449
	<i>A. J. Raeber, M. Moser, and B. Oesch</i>		39.3	The factors that determined the course of the epidemic	452
35.1	Introduction	408	40	The Causes of the BSE Epidemic	464
35.2	Properties of the normal and disease-associated form of the prion protein	408		<i>S. Dahms and B. Hörnlimann</i>	
35.3	Rapid tests approved by European authorities	408	40.1	Introduction	464
35.4	Ante mortem TSE test development	414	40.2	The case-series study: development of the feed-borne hypothesis	464
35.5	Identification of atypical BSE strains	416	40.3	The case-control study: investigations on the feed-borne hypothesis	465
<hr/>					
Topic VI: Epidemiology					
<hr/>					
36	Epidemiology and Risk Factors of Creutzfeldt-Jakob Disease	423	Topic VII: Transmissibility		
	<i>I. Zerr and S. Poser</i>		<hr/>		
36.1	Introduction	423	41	The Experimental Transmissibility of Prions and Infectivity Distribution in the Body	473
36.2	Descriptive epidemiology	423		<i>M. H. Groschup, M. Geissen, and A. Buschmann</i>	
36.3	Risk factors for sporadic CJD	425			
36.4	Epidemiology and risk factors of acquired forms of CJD	427			

41.1	Introduction	473	44.3	Prerequisites for the efficiency of chemical disinfectants	506
41.2	Brief historical overview	473	44.4	Testing for prion depletion and inactivation efficiency	506
41.3	Design of experimental transmission studies	473	44.5	Chemical disinfectants suitable for the inactivation of prions	508
41.4	Experimental transmissibility of human prion diseases	475	44.6	Chemical disinfectants unsuitable or less suitable for the inactivation of prions	511
41.5	Experimental transmissibility of animal prion diseases	476	45	Thermal Inactivation of Prions	515
41.6	Infectivity distribution in peripheral organs	477		<i>R.C. Oberthür, H. Müller, and D. Riesner</i>	
41.7	Pathogenesis studies	478	45.1	Introduction	515
42	Iatrogenic and “Natural” Transmissibility of Prion Diseases	483	45.2	Physical chemistry of heat inactivation of complex biological structures	515
	<i>M.H. Groschup, B. Höرنlimann, and A. Buschmann</i>		45.3	Kinetics of thermal denaturation and inactivation	516
42.1	Introduction	483	45.4	Experimental setup for the thermal inactivation of a specimen	517
42.2	Natural transmission within one species	486	45.5	Results of inactivation studies	519
42.3	Natural transmission of scrapie to other species	489	45.6	Inactivation of prions under oleochemical conditions	522
42.4	Natural transmission of BSE to other species	489	45.7	Practical and theoretical implications	523
42.5	Iatrogenic transmission in human and veterinary medicine	490			
42.6	Genetically determined susceptibility	491			
<hr/>					
Topic VIII: Agent Inactivation					
<hr/>					
43	Inactivation in Practice – Risk Assessment and Validation for Food Gelatin	499	46	Prevention of Prion Diseases in the Production of Medicinal Products, Medical Devices, and Cosmetics	529
	<i>S.C. MacDiarmid</i>			<i>M. Ruffing, H. Windemann, and J. Schaefer</i>	
43.1	Introduction	499	46.1	Introduction	529
43.2	Raw materials	499	46.2	Regulations to prevent the transmission of prion diseases by medicinal products and cosmetics	529
43.3	Dilution	500	46.3	Evaluation of the risk of medicinal products transmitting prion diseases	533
43.4	Acid treatment	501	46.4	Regulations for specific materials used in the production of medicinal products	538
43.5	Alkaline treatment	501	46.5	Regulations to prevent the transmission of prions by medical devices	541
43.6	Further acid treatment	502	47	Prevention of the Transmission of Prion Diseases in Healthcare Settings	546
43.7	Extraction of gelatin	502		<i>B. Höرنlimann, G. Pauli, K. Lemmer, M. Beekes, and M. Mielke</i>	
43.8	Experimental studies	502	47.1	Introduction	546
43.9	Conclusions	502	47.2	Patient care	547
44	Chemical Disinfection and Inactivation of Prions	504	47.3	Risk of accidental occupational transmission in nosocomial and other healthcare settings	547
	<i>B. Höرنlimann, W.J. Schulz-Schaeffer, K. Roth, Z.-X. Yan, H. Müller, R.C. Oberthür, and D. Riesner</i>				
44.1	Introduction	504			
44.2	Basic knowledge regarding the chemical inactivation of prions	505			

47.4	Iatrogenic transmission of human TSEs: retrospective findings and current risk assessment	547	Topic X: Risk Assessment	
47.5	Preventive measures for handling CSF and tissue samples	550	50	Evidence for a Link between Variant Creutzfeldt-Jakob Disease and Bovine Spongiform Encephalopathy
47.6	Transmission through blood and blood products	550		<i>M. E. Bruce, R. G. Will, J. W. Ironside, and H. Fraser</i>
47.7	Precautionary measures to minimize the risk of transmission via surgical interventions on patients with an evident or potential risk of CJD or vCJD	551	50.1	Introduction
47.8	Disinfection and sterilization of instruments and materials	552	50.2	TSE strain discrimination in mice
47.9	Decontamination of instruments following surgery on patients without any specific signs or symptoms pointing to a risk of transmission	552	50.3	Transmissions of Animal TSEs to mice
47.10	Prevention in specific areas	555	50.4	Transmissions of vCJD and sCJD to mice
47.11	Handling of corpses prior to interment	557	50.5	Conclusions
47.12	Waste disposal in hospitals and laboratories	557	51	Risk Assessment of Transmitting Prion Diseases through Blood, Cornea, and Dura Mater
48	Precautionary Measures for Autopsies Performed in Cases of Suspected Prion Disease	561		<i>J. Löwer and T. R. Kreil</i>
	<i>W. J. Schulz-Schaeffer, A. Giese, and H. Kretzschmar</i>		51.1	Introduction
48.1	Introduction	561	51.2	Blood
48.2	Performing the autopsy	562	51.3	Cornea
48.3	Decontamination and resistance of the infectious agent	563	51.4	Dura mater
49	Prevention of Prion Diseases in Research Laboratories	565	52	BSE Risk Assessment and Minimization
	<i>A. J. Raeber and A. Aguzzi</i>			<i>R. C. Oberthür, A. A. de Koeijer, B. E. C. Schreuder, and S. C. MacDiarmid</i>
49.1	Introduction	565	52.1	Introduction
49.2	Risk categorization of prions	565	52.2	Definition of the term "risk"
49.3	Risk assessment for work with prions and prion proteins	566	52.3	Dose–response relationship in BSE
49.4	Risk classification for work with prions and prion proteins	566	52.4	Reproduction number
49.5	Containment of laboratory work with prions	567	52.5	Reproduction number in Great Britain over time
49.6	Inactivation of prions in research laboratories	567	52.6	BSE risk minimization within the cattle population
49.7	Post-exposure prophylaxis following spills and accidents	568	52.7	BSE risk minimization from cattle to humans
49.8	Further useful information	569	52.8	Control of the efficiency of BSE risk minimization
			53	BSE control – Internationally Recommended Approaches
				<i>S. C. MacDiarmid, P. Infanger, and B. Hörnlimann</i>
			53.1	Introduction
			53.2	Measures in response to the first case of BSE in a country
			53.3	Measures for surveillance, prevention, and control of a BSE epidemic

54	Atypical Scrapie–Nor98 <i>S.L. Benestad and B. Bratberg</i>	630	56.2	Sheep PrP gene (<i>Prnp</i>) and its variations	640
54.1	Introduction	630	56.3	Sheep PrP genotypes and association with susceptibility to TSEs	642
54.2	TSE surveillance program launched for small ruminants	630	56.4	Methods of genotyping sheep	643
54.3	Particularity of clinical signs of atypical scrapie	630	57	Scrapie Control at the National Level: The Norwegian Example <i>K. R. Alvseike, I. Melkild, and K. Thorud</i>	648
53.4	Particularity of genetics	631	57.1	Introduction	648
54.5	Particularity of the pathology	631	57.2	Number of scrapie cases in Norway	648
54.6	Particularity of the diagnosis	632	57.3	Scrapie surveillance	649
54.7	The origin of atypical scrapie	633	57.4	Control and eradication of scrapie	650
55	Scrapie Control – Internationally Recommended Approaches <i>M.G. Doherr and N. Hunter</i>	635	57.5	Scrapie prevention	652
55.1	Introduction	635	Epilogue		655
55.2	Criteria to assess the scrapie status of a country or region	636	Appendix 1: Major Categories of Infectivity (WHO)		657
55.3	Disease monitoring	636	Appendix 2: Bovine Spongiform Encephalopathy (OIE)		665
55.4	Measures to control scrapie in a country or region	637	Appendix 3: Scrapie (OIE)		671
55.5	Historical scrapie situation and potential import routes	638	Authors Index		675
55.6	National animal identification and tracing system	638	Subject Index		683
55.7	Genetic influences	638			
56	The PrP Genotype as a Marker for Scrapie Susceptibility in Sheep <i>N. Hunter, and A. Bossers</i>	640			
56.1	Introduction	640			